Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2

Biochemical and Biophysical Research Communications
Wonhwa LeeJong-Sup Bae

Abstract

Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, has been reported to attenuate myocardial ischemia and reperfusion injury and inflammatory or oxidative responses. The expression level of secretory group IIA phospholipase A2 (sPLA2-IIA) is elevated in inflammatory diseases. Lipopolysaccharide (LPS) upregulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Here, EX4 was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mice. Pre-treatment of cells or mice with EX4 inhibited LPS-induced sPLA2-IIA expression and activity. Additionally, EX4 suppressed LPS-induced activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. Therefore, these results show that EX4 inhibited LPS-induced expression of sPLA2-IIA by suppressing cPLA2 and ERK 1/2.

References

Oct 1, 1977·Journal of Neurology, Neurosurgery, and Psychiatry·R L CarassoM Streifler
Feb 1, 1989·Klinische Wochenschrift·C WaydhasL Schweiberer
Jan 1, 1997·Trends in Biochemical Sciences·E A Dennis
Sep 3, 1998·The Journal of Biological Chemistry·C M MounierJ H Griffin
May 20, 1999·Annual Review of Pharmacology and Toxicology·J BalsindeE A Dennis
May 21, 1999·Biochemical and Biophysical Research Communications·S J VerselisJ W Fett
Nov 18, 2000·Biochimica Et Biophysica Acta·D A Six, E A Dennis
Nov 16, 2002·Prostaglandins & Other Lipid Mediators·Ichiro Kudo, Makoto Murakami
Dec 28, 2002·Chemical Senses·Andrew Kurt Thaw, Thomas J Quinn
Jan 1, 2003·Biochemical and Biophysical Research Communications·Grietje Ch BeckMarietta Kaszkin
Oct 15, 2005·Nature Reviews. Drug Discovery·Jon A BurasMichail Sitkovsky
Dec 24, 2005·Physiological Reviews·Dolly Mehta, Asrar B Malik
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
May 25, 2006·Neuroscience Research·Takashi IwaiJun-Ichiro Oka
Oct 20, 2006·The New England Journal of Medicine·James A Russell
Dec 11, 2007·The Journal of Biological Chemistry·Wen TianWonhwa Cho
Jan 10, 2009·Nature Protocols·Daniel RittirschPeter A Ward
Sep 18, 2009·The Journal of Clinical Investigation·Peter BalukDonald M McDonald
May 8, 2010·Arteriosclerosis, Thrombosis, and Vascular Biology·Hisko OeseburgHerman H W Silljé
Dec 21, 2010·Cardiovascular Therapeutics·Theodore Okerson, Robert J Chilton
Jul 20, 2013·Cardiovascular Therapeutics·Daniel Lorber

❮ Previous
Next ❯

Citations

Oct 21, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Vikram JoshiBannikuppe Sannanaik Vishwanath

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.